Business
Mesoblast reveals more COVID trials needed, shares tumble – Sydney Morning Herald
The Melbourne biotech has been advised by the US medicines regulator that it will need to run another trial of its COVID-19 treatment…
Stem cell treatments maker Mesoblast faces a new hurdle after the US medicines regulator told the company it would need to run another trial of its COVID-19 treatment before it could apply for emergency approvals.
Shares in the Melbourne biotech fell 15.9…
Continue Reading
-
Business20 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
Noosa News21 hours agoBroncos staffer who guided Mam through crash crisis admits to drink-driving
-
Noosa News22 hours agoQueenslanders to continue legal challenges against COVID-19 directives after successful appeal
-
Noosa News15 hours agoRacing Queensland responds to criticism of ‘deadliest’ greyhound track